Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk vaccines gmbh - davični toksoid; tetanusni toksoid - suspenzija za injiciranje - davični toksoid 2 i.e. / 0,5 ml  tetanusni toksoid20 i.e. / 0,5 ml; tetanusni toksoid 20 i.e. / 0,5 ml - tetanusni toksoid v kombinaciji z davičnim toksoidom

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk vaccines gmbh - tetanusni toksoid - suspenzija za injiciranje - tetanusni toksoid 40 i.e. / 0,5 ml - tetanusni toksoid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

cz vaccines -

Evropska unija - slovenščina - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur s.a. - split virus influence, inaktivirano, ki vsebujejo antigen*: a/california/7/2009 (h1n1)v, kot sev (x-179a)*razmnožujejo v jajca. - influenza, human; immunization; disease outbreaks - cepiva - preprečevanje gripe v uradno prijavljeni pandemični situaciji. pandemije gripe cepiva je treba uporabljati v skladu z uradnimi smernice.

Evropska unija - slovenščina - EMA (European Medicines Agency)

intervet international bv - prašičji cirkovirus tipa 2 orf2 podenotnega antigena - imunologija za suidae - prašiči - za aktivno imunizacijo prašičev za zmanjšanje obremenitve virusa v krvi in ​​limfnih tkivih in za zmanjšanje izgube teže, povezane z okužbo s prašiči-circovirusom tipa 2, ki se je zgodila med obdobjem pitanja. nastop odpornost: 2 weeksduration imunosti: 22 tednov.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokni - cepiva - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - pnevmokokne okužbe - cepiva - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. glej poglavja 4. 4 in 5. 1 za informacije o zaščiti proti specifičnim pnevmokoknim serotipom. apexxnar should be used in accordance with official recommendations. .

Evropska unija - slovenščina - EMA (European Medicines Agency)

intervet international bv - f4ab (k88ab) fimbrial adhesin, f4ac (k88ac) fimbrial adhesin, f5 (k99) fimbrial adhesin, f6 (987p) fimbrial adhesin, lt toxoid - imunologija - prašiči (mladice in svinje) - za pasivno imunizacijo za pujske z aktivno imunizacijo za svinje / brejih za zmanjšanje umrljivosti in kliničnih znakov, kot so driska zaradi novorojenčku enterotoxicosis v prvih dneh življenja, ki so jo povzročili tisti, e. coli, ki izražajo fimbrijalne adhezine f4ab (k88ab), f4ac (k88ac), f5 (k99) ali f6 (987p).

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.